<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="implemented. Immune-modulating therapies such as the fumerates, sphinogosine-1P modulators, and" exact="natalizumab" post="may be anecdotally preferred over cell-depleting immunosuppressants during the"/>
 <result pre="view of its infectious side-effect profile, it is possible that" exact="teriflunomide" post="my slightly increase the susceptibility to SARS-CoV-2. However, it"/>
 <result pre="it is perhaps relatively safe to continue ongoing treatment with" exact="teriflunomide" post="and to start it in patients newly diagnosed with"/>
 <result pre="One fatal case of COVID-19 infection in a patient taking" exact="teriflunomide" post="has been reported but the patient had advanced secondary"/>
 <result pre="[38]. Seven other cases of COVID-19 infection in patients taking" exact="teriflunomide" post="have been reported to the time of this writing,"/>
 <result pre="time of this writing, all with self-limiting courses despite continued" exact="teriflunomide" post="therapy during the infection in most of them [39–41]."/>
 <result pre="cases on social media [42]. Based on influenza vaccine studies," exact="teriflunomide" post="is unlikely to reduce the protective immune response against"/>
 <result pre="not receiving immunotherapies has been described in a patient taking" exact="teriflunomide" post="after COVID-19 infection [41]. Live-attenuated vaccines are not recommended"/>
 <result pre="cytokine storm has been proposed and a clinical trial of" exact="fingolimod" post="in patients with COVID-19 is currently ongoing (ClinicalTrials.gov Identifier:"/>
 <result pre="infected with COVID-19. Two cases of COVID-19 worsening after stopping" exact="fingolimod" post="have been reported [56, 57]. Treatment interruption may be"/>
 <result pre="lymphocytes on infection risk is not well defined [58]. Stopping" exact="fingolimod" post="has been linked to severe rebound MS activity, thus"/>
 <result pre="additional cases of COVID-19 infection in patients with MS taking" exact="fingolimod" post="have been reported to the time of this writing"/>
 <result pre="a severe course was described in two patients who stopped" exact="fingolimod" post="treatment during the infection as mentioned earlier and in"/>
 <result pre="earlier and in one additional patient who improved after delaying" exact="fingolimod" post="treatment. Some of the patients with a mild course"/>
 <result pre="Some of the patients with a mild course temporarily interrupted" exact="fingolimod" post="treatment during their COVID-19 infection and some continued treatment"/>
 <result pre="addition, one of the reported patients with COVID-19 infection taking" exact="fingolimod" post="was noted to have attenuated production of anti-SARS-CoV-2 antibodies"/>
 <result pre="linked to lymphopenia. Infectious Side Effects It is known that" exact="natalizumab" post="increases the risk of PML more than all other"/>
 <result pre="(8% vs 4% placebo) were commonly observed in patients taking" exact="natalizumab" post="[64]. Fatal cases of herpetic encephalitis and meningitis were"/>
 <result pre="Strategies Being a non cell-depleting agent, it is unlikely that" exact="natalizumab" post="significantly increases SARS-CoV-2 susceptibility. Its infectious side-effect profile suggests"/>
 <result pre="Based on influenza vaccine studies, it is also unlikely that" exact="natalizumab" post="will have a negative impact on the future SARS-CoV-2"/>
 <result pre="Overall, it is likely safe to continue ongoing treatment with" exact="natalizumab" post="during the COVID-19 pandemic including in infected patients. It"/>
 <result pre="also raises concerns about the potential for SARS-CoV-2 encephalitis if" exact="natalizumab" post="is used in patients with COVID-19 [66]. As opposed"/>
 <result pre="two cases of COVID-19 infection in patients with MS taking" exact="natalizumab" post="have been reported [68, 69]. Both patients had mild"/>
 <result pre="infusion centers but the exposure risk is less compared with" exact="natalizumab" post="because of the less frequent dosing (6-monthly maintenance infusions)."/>
 <result pre="on non-depleting DMTs during the pandemic. For highly active MS," exact="natalizumab" post="may be a safer and equally potent option for"/>
 <result pre="the early B-cell reconstitution in the absence of T cells," exact="alemtuzumab" post="can cause several autoimmune disorders including thyroid disease, idiopathic"/>
 <result pre="cause neutropenia and pancytopenia. Infectious Side Effects Patients treated with" exact="alemtuzumab" post="have a higher risk of infection. In clinical studies,"/>
 <result pre="In clinical studies, infections occurred in 71% of patients taking" exact="alemtuzumab" post="vs 53% of patients taking IFN-β1a [86]. These infections"/>
 <result pre="vs 4%). Serious infections occurred in 3% of patients taking" exact="alemtuzumab" post="vs 1% of patients taking IFN-β1a. These included pneumonia"/>
 <result pre="and B cells as well as some innate immune cells," exact="alemtuzumab" post="may impact the early and long-term immunity against SARS-CoV-2"/>
 <result pre="routes but the infusion frequency is less than that of" exact="natalizumab" post="and ocrelizumab considering the limited number of infusions needed"/>
 <result pre="case reports of COVID-19 infection during the cell-depletion phase of" exact="alemtuzumab" post="therapy have been described at the time of this"/>
 <result pre="writing [87, 88]. Both patients received their second cycle of" exact="alemtuzumab" post="therapy during the peak of the pandemic and developed"/>
 <result pre="moderate (grade 2) lymphopenia. It is unclear if treatment with" exact="alemtuzumab" post="increased the susceptibility to SARS-CoV-2 infection in those patients"/>
 <result pre="immune reconstitution phase after completing two or three rounds of" exact="alemtuzumab" post="and returning to normal or near-normal lymphocyte counts are"/>
 <result pre="The authors of this study speculated that immune reconstitution after" exact="alemtuzumab" post="therapy may provide partial protection against severe COVID-19 infection,"/>
 <result pre="including the two reported COVID-19 confirmed cases, suggests that redosing" exact="alemtuzumab" post="during the pandemic in high-risk areas may be unsafe."/>
 <result pre="high risk of catching the infection is the link between" exact="alemtuzumab" post="and the risk of stroke and cervicocephalic arterial dissection"/>
 <result pre="thrombosis and intracerebral hemorrhage [94] if patients are re-dosed with" exact="alemtuzumab" post="during infection or if they catch the infection shortly"/>
 <result pre="the infection shortly after redosing. Staring a new treatment with" exact="alemtuzumab" post="during the pandemic is not preferred and should only"/>
 <result pre="protein or inactivated vaccine is advisable in patients treated with" exact="alemtuzumab" post="during the cell-depletion phase. Patients taking alemtuzumab who are"/>
 <result pre="patients treated with alemtuzumab during the cell-depletion phase. Patients taking" exact="alemtuzumab" post="who are in the depletion phase should follow strict"/>
 <result pre="counts over several months. Contrary to alemtuzumab, the effect of" exact="cladribine" post="on the innate immune cells is limited, although rare"/>
 <result pre="In clinical studies, infections occurred in 49% of patients taking" exact="cladribine" post="compared with 44% in the placebo group. There was"/>
 <result pre="[97]. In terms of serious infections, 6% of patients taking" exact="cladribine" post="developed a herpetic infection compared with 2% in the"/>
 <result pre="viral vector vaccines. It might be relatively safer compared with" exact="alemtuzumab" post="owing to its oral route of administration and lesser"/>
 <result pre="been any confirmed cases of COVID-19 infection in patients receiving" exact="cladribine" post="but one study found a trend towards higher COVID-19"/>
 <result pre="a trend towards higher COVID-19 suggestive symptoms in patients receiving" exact="cladribine" post="compared with injectable therapies [99]. Patients in the depletion"/>
 <result pre="safer DMT should also be considered. Starting new treatment with" exact="cladribine" post="is not preferred during the pandemic except if extremely"/>
 <result pre="the future SARS-CoV-2 vaccine. Cladribine may be relatively safer than" exact="alemtuzumab" post="given the oral route of administration, the limited impact"/>
 <result pre="of differentiation 19, DMF dimethyl fumarate, DRF diroximel fumarate, GA" exact="glatiramer acetate," post="Ig immunoglobulin, IVIG intravenous immunoglobulins, JCV John Cunningham virus,"/>
 <result pre="infectious issues: update 2013Clin Exp Immunol2014175342543824134716 25.HungIFLungKCTsoEYet al.Triple combination of" exact="interferon beta-1b," post="lopinavir–ritonavir, and ribavirin in the treatment of patients admitted"/>
 <result pre="Exp Immunol2014175342543824134716 25.HungIFLungKCTsoEYet al.Triple combination of interferon beta-1b, lopinavir–ritonavir, and" exact="ribavirin" post="in the treatment of patients admitted to hospital with"/>
 <result pre="in patients with multiple sclerosis receiving interferon beta-1aNeurology200565121964196616380621 27.CohenJABarkhofFComiGet al.Oral" exact="fingolimod" post="or intramuscular interferon for relapsing multiple sclerosisN Engl J"/>
 <result pre="for relapsing multiple sclerosisN Engl J Med201036240241520089954 28.HauserSLBar-OrAComiGet al.Ocrelizumab versus" exact="interferon beta-1a" post="in relapsing multiple sclerosisN Engl J Med2017376322123428002679 29.CrossAHNaismithRTEstablished and"/>
 <result pre="multiple sclerosisJ Neurol202032494856 40.MöhnNSakerFBondaVet al.Mild COVID-19 symptoms despite treatment with" exact="teriflunomide" post="and high-dose methylprednisolone due to multiple sclerosis relapseJ Neurol202032494855"/>
 <result pre="40.MöhnNSakerFBondaVet al.Mild COVID-19 symptoms despite treatment with teriflunomide and high-dose" exact="methylprednisolone" post="due to multiple sclerosis relapseJ Neurol202032494855 41.LucaBTommasoGBavaroDFet al.Seroconversion and"/>
 <result pre="course of COVID-19 in patients with multiple sclerosis treated with" exact="fingolimod" post="and teriflunomideJ Neurol Sci202041611701132650143 42.NesbittCRathLYehWZet al.MSCOVID19: using social media"/>
 <result pre="in patients with multiple sclerosisNeurology201381655255823851964 44.O’ConnorPWolinskyJSConfavreuxCet al.Randomized trial of oral" exact="teriflunomide" post="for relapsing multiple sclerosisN Engl J Med2011365141293130321991951 45.ConfavreuxCO’ConnorPComiGet al.Oral"/>
 <result pre="teriflunomide for relapsing multiple sclerosisN Engl J Med2011365141293130321991951 45.ConfavreuxCO’ConnorPComiGet al.Oral" exact="teriflunomide" post="for patients with relapsing multiple sclerosis (TOWER): a randomized,"/>
 <result pre="fumarateNeurol Neuroimmunol Neuroinflamm201851e40929159204 52.CohenJAComiGSelmajKWet al.Safety and efficacy of ozanimod versus" exact="interferon beta-1a" post="in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month,"/>
 <result pre="Accessed 28 July 2020. 56.Gomez-MayordomoVMontero-EscribanoPMatías-GuiuJAGonzález-GarcíaNPorta-EtessamJMatías-GuiuJClinical exacerbation of SARS-CoV2 infection after" exact="fingolimod" post="withdrawalJ Med Virol202032644205 57.Valencia-SanchezCWingerchukDMA fine balance: immunosuppression and immunotherapy"/>
 <result pre="therapiesMult Scler Relat Disord20203910207332334820 67.Zhovtis RyersonLFrohmanTCFoleyJet al.Extended interval dosing of" exact="natalizumab" post="in multiple sclerosisJ Neurol Neurosurg Psychiatry201687888588926917698 68.BorrielloGIannielloACOVID-19 occurring during"/>
 <result pre="youngN Engl J Med202038220e6032343504 95.GiovannoniGComiGCookSet al.A placebo-controlled trial of oral" exact="cladribine" post="for relapsing multiple sclerosisN Engl J Med2010362541642620089960 96.GiovannoniGCladribine to"/>
 <result pre="2019. https://www.emdserono.com/us-en/pi/mavenclad-pi.pdf. Accessed 28 July 2020. 98.StuveOSoelberg SoerensenPLeistTet al.Effects of" exact="cladribine" post="tablets on lymphocyte subsets in patients with multiple sclerosis:"/>
</results>
